In the January JAMA Neurology, researchers formally published the results of the Phase 3 trial of Dimebon®, aka latrepirdine, in Huntington’s disease patients. In April 2011, the drug’s sponsors, Medivation Inc. and Pfizer, announced that Dimebon failed to show efficacy in the six-month HORIZON trial, which enrolled 403 people with Huntington’s disease in 11 countries (see ARF related news story). The drug had shown hints of cognitive benefit in a Phase 2 trial (see ARF related news story), but in Phase 3, people taking Dimebon showed no improvement over controls on the Mini-Mental State Examination or the Clinician Interview-Based Impression of Change. The Huntington Study Group and the European Huntington’s Disease Network carried out the trial.

The findings echo Dimebon's tribulations in Alzheimer’s disease, where promising Phase 2 results (see ARF related news story) evaporated in Phase 3 (see ARF related news story; ARF news story).—Madolyn Bowman Rogers


Comments on this content

No Available Comments

Make a Comment

To make a comment you must login or register.


News Citations

  1. No Effect Seen in Huntington’s Disease Trial of Dimebon
  2. Dimebon for HD—A Hint of Cognitive Benefit?
  3. Boston: Clinical Trial Results for Dimebon Unveiled
  4. Dimebon Disappoints in Phase 3 Trial
  5. CONCERT Trial of Dimebon Falls Flat

External Citations

  1. HORIZON trial
  2. Phase 2 trial

Further Reading